1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Viatris: Watch Out For Potential Complex Injectable Launches In 2023

As Firm Welcomes Generics ‘Momentum We Have Never Seen Before’

 
• By Dean Rudge

Viatris has again the lauded the potential of its complex injectables and steriles pipeline, as it looks to build a business generating revenues of up to $1bn per year within the next five years.

NWW Binoculaurs
• Source: Shutterstock

Viatris has guided for certain of its pipeline of complex injectable and sterile products in the US to come to market “if we are optimistic later this year or early next year,” as it continues to aim towards building a franchise worth, it believes, at least $1bn per year in peak net sales by 2027 or 2028.

The company has eight first-to-market opportunities that are currently under regulatory review from within its complex injectable/steriles pipeline, including a generic version of Novo Nordisk’s GLP-1 receptor agonist Wegovy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.